Hefiya

Hefiya is a pharmaceutical product that contains the biologic agent adalimumab. It is provided as an injectable preparation, with the specific strength and dosage form defined by the European Union prescribing information. As a tumor necrosis factor (TNF) inhibitor, it is used under medical supervision for approved inflammatory conditions. The medication is prescribed for patients who have an inadequate response to systemic therapies and is administered by a healthcare professional.

Hefiya (adalimumab) is indicated for several chronic inflammatory disorders, including those where suppression of tumor necrosis factor‑α is clinically beneficial.

- Rheumatoid arthritis in adults who have an inadequate response to conventional disease‑modifying antirheumatic drugs. - Psoriatic arthritis for patients with active joint disease despite prior therapy. - Ankylosing spondylitis in adults with active disease not controlled by NSAIDs. - Moderate to severe Crohn’s disease refractory to conventional treatment. - Moderate to severe ulcerative colitis unresponsive to standard therapy. - Plaque psoriasis in adults requiring systemic treatment.

Adalimumab may cause a range of adverse reactions, which are generally categorized by frequency and severity overall.

Common: - Injection site reactions such as redness, swelling, itching, or pain at the administration site. - Upper respiratory tract infections, including common cold, sinusitis, and nasopharyngitis. - Headache, ranging from mild to moderate intensity. - Nausea, often transient and mild. - Fatigue or general feeling of tiredness, occasionally affecting daily activities.

Serious: - Serious infections, for example tuberculosis, bacterial sepsis, fungal infections, and opportunistic pathogens. - Reactivation of hepatitis B in patients with prior infection. - Malignancies, including lymphoma and other rare cancers. - Demyelinating disorders such as multiple sclerosis‑like events. - Exacerbation of congestive heart failure.

When prescribing Hefiya, clinicians should consider several precautionary measures to ensure patient safety and optimal therapeutic outcomes.

- Screen for active or latent tuberculosis before initiating therapy. - Evaluate for chronic infections such as hepatitis B or C and manage accordingly. - Assess patient history for demyelinating disease, heart failure, or malignancy. - Monitor for signs of serious infection during treatment. - Use caution in pregnant or breastfeeding women; discuss risks and benefits. - Adjust dosing in patients with severe renal or hepatic impairment as recommended.

Adalimumab can interact with other medicines, potentially altering its efficacy or increasing safety risks.

Avoid: - Live vaccines should be avoided because immunosuppression from adalimumab can allow the attenuated pathogen to cause infection. - Concomitant use with other biologic immunosuppressants (for example, abatacept or rituximab) is generally avoided due to a substantially increased risk of serious infections.

Use with caution: - Methotrexate or azathioprine may augment immunosuppressive effects; patients should be monitored for infection signs and blood counts. - Antifungal agents such as azoles can affect the metabolism of adalimumab; dose adjustments may be necessary. - Cyclosporine or tacrolimus may increase hepatic stress; liver function tests should be performed regularly.